| Name | Title | Contact Details |
|---|
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
GWARC, Inc. is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pacific Alliance Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Pacific Alliance Medical Center is based in Los Angeles, CA. You can find more information on Pacific Alliance Medical Center at www.pamc.net
Neurowave Medical Technologies is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Creative Health Care Management is a Hopkins, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.